| Controversy around airborne versus droplet transmission of respiratory viruses: implication for infection prevention |
47 |
| Influenza virus polymerase inhibitors in clinical development |
42 |
| Invasive pulmonary aspergillosis complicating severe influenza: epidemiology, diagnosis and treatment |
27 |
| Human noroviruses: recent advances in a 50-year history |
24 |
| Current and new rotavirus vaccines |
22 |
| Scaling up HIV self-testing in sub-Saharan Africa: a review of technology, policy and evidence |
21 |
| Neuraminidase inhibitor resistance in influenza: a clinical perspective |
19 |
| Recent insights into Shigella: a major contributor to the global diarrhoeal disease burden |
13 |
| The impact of malnutrition on childhood infections |
12 |
| New antibiotics for ventilator-associated pneumonia |
12 |
| Managing Acinetobacter baumannii infections |
12 |
| Typhoid and paratyphoid fever: a call to action |
12 |
| Zika virus as a sexually transmitted pathogen |
12 |
| Human adenovirus infections: update and consideration of mechanisms of viral persistence |
11 |
| Sexually transmitted hepatitis C infection: the evolving epidemic in HIV-positive and HIV-negative MSM |
11 |
| How to optimize antibiotic pharmacokinetic/pharmacodynamics for Gram-negative infections in critically ill patients |
10 |
| Optimizing therapy in carbapenem-resistant Enterobacteriaceae infections |
10 |
| Invasive fungal disease and cytomegalovirus infection: is there an association? |
10 |
| BK polyomavirus-specific antibody and T-cell responses in kidney transplantation: update |
10 |
| Addressing unhealthy alcohol use among people living with HIV: recent advances and research directions |
10 |
| When do co-infections matter? |
9 |
| The biofilm in bacterial vaginosis: implications for epidemiology, diagnosis and treatment: 2018 update |
9 |
| Epidemiology of community-acquired bacterial meningitis |
9 |
| Principles and practice of antibiotic stewardship in the management of diabetic foot infections |
9 |
| Epidemiology of carbapenem-resistant Gram-negative infections globally |
9 |
| Polyclonal and monoclonal antibodies for the treatment of influenza |
8 |
| The role of new beta-lactamase inhibitors in gram-negative infections |
8 |
| Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship |
8 |
| Treatment of cryptococcosis in non-HIV immunocompromised patients |
8 |
| Getting hypervirulent Klebsiella pneumoniae on the radar screen |
8 |
| Congenital Chagas disease: current diagnostics, limitations and future perspectives |
8 |
| Rabies: changing prophylaxis and new insights in pathophysiology |
8 |
| Pathophysiology, clinical presentation, and treatment of coma and acute kidney injury complicating falciparum malaria |
7 |
| Assessing inflammation and its role in comorbidities among persons living with HIV |
7 |
| Neisseria gonorrhoeae vaccine development: hope on the horizon? |
7 |
| Iron: an essential nutrient for Aspergillus fumigatus and a fulcrum for pathogenesis |
7 |
| Herpes simplex virus encephalitis update |
7 |
| Optimal duration of antibiotic treatment in Gram-negative infections |
7 |
| New antibiotics for community-acquired pneumonia |
6 |
| Infectious causes of stroke |
6 |
| Dolutegravir resistance mutations: lessons from monotherapy studies |
6 |
| Norovirus in health care and implications for the immunocompromised host |
6 |
| HIV outcomes among migrants from low-income and middle-income countries living in high-income countries: a review of recent evidence |
6 |
| Pharmacokinetics and pharmacodynamics of antibiotics in central nervous system infections |
6 |
| Recent epidemiology of sexually transmissible enteric infections in men who have sex with men |
6 |
| Treatment of severe skin and soft tissue infections: a review |
5 |
| The role of dalbavancin in skin and soft tissue infections |
5 |
| Scaling up pre-exposure prophylaxis in sub-Saharan Africa |
5 |
| Cholera: recent updates |
5 |
| Treatment of influenza with neuraminidase inhibitors |
5 |
